Alexion Pharmaceuticals: “Worst-Case Scenario Averted”
January 05, 2017 at 11:04 AM EST
Alexion Pharmaceuticals ( ALXN ) is on a tear today after the company revealed in SEC filings that an audit committee decided that the drug maker didn’t need to restate its financials , bringing an end to an investigation into allegations of improper sales practices Investors were thrilled. The shares surged 8.1% to $137.41, and a trio of analysts have weighed in with high hopes for 2017 as investors refocus on the company’s fundamentals and pipeline
